Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Ulla Klaiber

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9287-1174; OpenAlex author ID A5037525502. Sources: OpenAlex.

Their work

Papers
31 (first author 8, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
118
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 7 papers · 2020: 5 papers · 2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 31

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  3. Standardized Approach to Superior Mesenteric Artery Resection for Locally Advanced Pancreatic Cancer. First author DOI 10.3791/68465↗
  4. Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1053/j.gastro.2024.05.028↗
  5. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Last author DOI 10.1097/js9.0000000000000792↗
  6. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  7. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  8. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival. First author DOI 10.1097/sla.0000000000005444↗
  9. Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. First author DOI 10.1097/sla.0000000000005481↗
  10. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  11. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. Co-author DOI 10.1245/s10434-022-12569-y↗
  12. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. Co-author DOI 10.1245/s10434-022-12901-6↗
  13. Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve. Co-author DOI 10.1097/sla.0000000000004054↗
  14. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  15. Prospective trial to evaluate the prognostic value of different nutritional assessment scores for survival in pancreatic ductal adenocarcinoma (NURIMAS Pancrea… First author DOI 10.1002/jcsm.12796↗
  16. [Surgery for periampullary pancreatic cancer]. First author DOI 10.1007/s00104-021-01462-1↗
  17. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003270↗
  18. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  19. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. Co-author DOI 10.1016/j.hpb.2019.06.012↗
  20. Fifty Years of Surgery for Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001634↗
  21. Response to the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". First author DOI 10.1097/sla.0000000000003651↗
  22. Response: the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good … First author DOI 10.1097/sla.0000000000003652↗
  23. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Co-author DOI 10.1002/bjs.11295↗
  24. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Co-author DOI 10.1016/j.ejso.2019.03.039↗
  25. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative ch… Co-author DOI 10.1136/bmjopen-2018-028696↗
  26. Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.27399↗
  27. Radical pancreatic cancer surgery-with arterial resection. Co-author DOI 10.21037/tgh.2019.01.07↗
  28. Adjuvant treatment for pancreatic cancer. Co-author DOI 10.21037/tgh.2019.04.04↗
  29. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. Co-author DOI 10.3389/fonc.2019.01501↗
  30. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1007/s00423-018-1724-8↗
  31. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 21 shared papers, 2018–2023 · strength 2.87
  2. Oliver Strobel · 16 shared papers, 2018–2026 · strength 2.65
  3. Markus Wolfgang Büchler · 16 shared papers, 2019–2023 · strength 2.18
  4. Carl-Stephan Leonhardt · 9 shared papers, 2018–2026 · strength 1.78
  5. Thomas P. Hank · 9 shared papers, 2021–2024 · strength 1.44
  6. Klaus Sahora · 5 shared papers, 2021–2025 · strength 1.10
  7. André L. Mihaljević · 7 shared papers, 2019–2023 · strength 0.96
  8. Martin Schindl · 4 shared papers, 2021–2024 · strength 0.73
  9. Max Heckler · 5 shared papers, 2019–2023 · strength 0.64
  10. Ulrike Heger · 5 shared papers, 2019–2023 · strength 0.63
  11. Masayuki Tanaka · 4 shared papers, 2019–2023 · strength 0.50
  12. John P. Neoptolemos · 4 shared papers, 2018–2021 · strength 0.47
  13. Andrew Louis Warshaw · 3 shared papers, 2022–2024 · strength 0.46
  14. Motaz Qadan · 3 shared papers, 2022–2024 · strength 0.46
  15. Keith D. Lillemoe · 3 shared papers, 2022–2024 · strength 0.46
  16. Caroline Sophie Verbeke · 2 shared papers, 2024 · strength 0.45
  17. Gerald W. Prager · 2 shared papers, 2023–2024 · strength 0.39
  18. Markus K. Diener · 4 shared papers, 2015–2022 · strength 0.38
  19. Christopher Lee Wolfgang · 2 shared papers, 2023–2026 · strength 0.35
  20. Cristina Rosa Ferrone · 2 shared papers, 2023–2024 · strength 0.34
  21. Carlos Fernández-del Castillo · 2 shared papers, 2022–2024 · strength 0.30
  22. Martin Loos · 2 shared papers, 2022–2023 · strength 0.30
  23. Asif Halimi · 2 shared papers, 2020–2026 · strength 0.25
  24. Johanna W. Wilmink · 2 shared papers, 2020–2026 · strength 0.25
  25. Bas Groot Koerkamp · 2 shared papers, 2020–2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.